康华生物
(300841)
| 流通市值：66.72亿 | | | 总市值：71.31亿 |
| 流通股本：1.22亿 | | | 总股本：1.30亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 304,516,598.33 | 513,320,495.38 | 1,151,045,280.7 | 943,132,559.99 |
| 交易性金融资产 | 728,710,366.48 | 541,833,781.13 | - | - |
| 应收票据及应收账款 | 1,293,202,869.88 | 1,193,572,117.12 | 1,225,517,096.57 | 1,315,557,236.92 |
| 应收账款 | 1,293,202,869.88 | 1,193,572,117.12 | 1,225,517,096.57 | 1,315,557,236.92 |
| 预付款项 | 8,886,504.82 | 11,679,493.79 | 4,058,548.01 | 8,268,679.07 |
| 其他应收款合计 | 1,216,247.1 | 21,305,433.25 | 293,182.29 | 1,381,952.2 |
| 存货 | 130,096,574.2 | 150,712,075.58 | 140,806,901.32 | 147,383,087.45 |
| 其他流动资产 | 1,913,907.96 | 1,615,542.73 | 1,474,277.28 | 323,011.22 |
| 流动资产合计 | 2,468,543,068.77 | 2,434,038,938.98 | 2,523,195,286.17 | 2,416,046,526.85 |
| 非流动资产: | | | | |
| 长期股权投资 | 6,280,086.33 | 6,280,086.33 | 6,280,086.33 | 6,353,329.95 |
| 其他非流动金融资产 | 396,173,212.43 | 398,138,400 | 398,138,400 | 406,155,607.36 |
| 固定资产 | 807,797,250.54 | 856,739,929.85 | 879,999,673.93 | 902,490,513.12 |
| 在建工程 | 2,366,731.47 | 1,577,820.98 | - | - |
| 无形资产 | 14,621,247.87 | 14,798,614.12 | 15,711,098.5 | 15,888,530.35 |
| 长期待摊费用 | 193,369,255.16 | 184,952,731.8 | 177,113,693 | 184,704,620.97 |
| 递延所得税资产 | 8,411,704.73 | 7,487,943.38 | 6,853,191.8 | 4,148,040.81 |
| 其他非流动资产 | 72,894,013.6 | 2,302,340.69 | 2,481,638.02 | 1,709,075.8 |
| 非流动资产合计 | 1,501,913,502.13 | 1,472,277,867.15 | 1,486,577,781.58 | 1,521,449,718.36 |
| 资产总计 | 3,970,456,570.9 | 3,906,316,806.13 | 4,009,773,067.75 | 3,937,496,245.21 |
| 流动负债: | | | | |
| 短期借款 | - | 30,106,110.72 | 139,896,059.65 | 149,883,253.92 |
| 应付票据及应付账款 | 4,905,998.58 | 12,130,644.28 | 2,952,102.54 | 1,977,018.32 |
| 其中：应付票据 | 789,900 | 789,900 | - | - |
| 应付账款 | 4,116,098.58 | 11,340,744.28 | 2,952,102.54 | 1,977,018.32 |
| 合同负债 | 493,146.57 | 423,364.92 | 505,871.96 | 439,662.14 |
| 应付职工薪酬 | 21,486,678.15 | 15,821,305.76 | 26,151,104.76 | 22,850,493.08 |
| 应交税费 | 28,669,904.76 | 29,932,970.55 | 30,579,660.4 | 22,682,803.4 |
| 其他应付款合计 | 267,067,245.51 | 220,076,870.44 | 239,221,775.94 | 215,032,614.08 |
| 其他流动负债 | 59,273.79 | 54,346.67 | 14,060.33 | 13,189.86 |
| 流动负债合计 | 322,682,247.36 | 308,545,613.34 | 439,320,635.58 | 412,879,034.8 |
| 非流动负债: | | | | |
| 预计负债 | 26,485,557.18 | 25,078,248.48 | 24,880,143.96 | 9,573,225.11 |
| 递延收益 | 7,594,733.15 | 7,853,644.52 | 8,112,555.89 | 8,371,467.26 |
| 递延所得税负债 | 58,450 | 16,150 | - | - |
| 非流动负债合计 | 34,138,740.33 | 32,948,043 | 32,992,699.85 | 17,944,692.37 |
| 负债合计 | 356,820,987.69 | 341,493,656.34 | 472,313,335.43 | 430,823,727.17 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 129,946,899 | 129,946,899 | 129,946,899 | 129,946,899 |
| 资本公积 | 861,151,773.51 | 861,151,773.51 | 861,151,773.51 | 861,151,773.51 |
| 盈余公积 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 |
| 未分配利润 | 2,555,211,686.2 | 2,506,399,252.78 | 2,479,035,835.31 | 2,448,248,621.03 |
| 归属于母公司股东权益合计 | 3,613,635,583.21 | 3,564,823,149.79 | 3,537,459,732.32 | 3,506,672,518.04 |
| 股东权益合计 | 3,613,635,583.21 | 3,564,823,149.79 | 3,537,459,732.32 | 3,506,672,518.04 |
| 负债和股东权益合计 | 3,970,456,570.9 | 3,906,316,806.13 | 4,009,773,067.75 | 3,937,496,245.21 |
| 公告日期 | 2026-08-18 | 2026-04-21 | 2026-04-21 | 2025-10-17 |
| 审计意见(境内) | | | 标准无保留意见 | |